Australian researchers have shown for the first time that a new drug used to treat breast cancer patients damages the store of immature eggs in the ovaries of mice.
Jul 1, 2020
0
55
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
Apr 28, 2020
0
178
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...
Dec 19, 2019
0
0
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.
Dec 3, 2019
0
2
A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings ...
Sep 30, 2019
0
1
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, ...
Sep 28, 2019
0
5
Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas ...
Jun 3, 2019
0
3
A drug could help slow the progression of some advanced ovarian cancers and extend the time that patients show no signs of disease, according to new clinical trial results.
Oct 25, 2018
0
11
